a new era for IPSC-MSC
Welcome to Kiji Therapeutics, an international biotech company based in France and Spain dedicated to delivering a new era of IPSC-MSC engineered cell therapy for inflammatory disease.
With a scientific foundation built upon collaboration with three renowned institutions – CIBER, Fundación Jiménez Díaz, and CIEMAT – KIJI Tx is delivering a new era of IPSC-MSC engineered cell therapy for the treatment of broad range of inflammatory diseases. These professionalized, engineered MSCs have strong preclinical data and the potential to finally fulfil the long-standing promise of MSCs. Our international team of experienced professionals is committed to bringing these innovative therapies to patients in need.
FIRST PRODUCT KJ01
Why do we need a paradigm for MSC :
We are developing gene engineered iPSC-MSCs with a superior demonstrated efficacy and improved manufacturing, consistency, and flexibility.
Our first products are IPSC-MSCS transduced with IL10 and CXCR4. Strong preclinical data show an improved efficacy through synergistic immunomodulation (IL10) and homing (CXCR4).
In addition, IPSC source offers the consistency needed to guarantee a quality manufacturing of the cells.